Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Dose-Ranging, Double Blind Study to Demonstrate the Safety and Efficacy of a CITI-002 Cream in the Seven Day Twice-Daily Treatment of Grade II or III Hemorrhoids

NCT05348200 is registered in ClinicalTrials.gov with Citius Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05348200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05348200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Dose-Ranging, Double Blind Study to Demonstrate the Safety and Efficacy of a CITI-002 Cream in the Seven Day Twice-Daily Treatment of Grade II or III Hemorrhoids
Lead sponsor
Citius Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 22, 2022
Completion date
May 17, 2023
Enrollment
304 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hemorrhoids